Skip to main content
Industry News
Study: New probiotic improves glycemic control in T2D

Type 2 diabetes patients undergoing metformin treatment experienced reductions in blood glucose and hemoglobin A1C by also taking a novel probiotic product containing certain microbes lacking in diabetes patients, compared with those who received placebo instead of the probiotic product. The small study in BMJ Open Diabetes Research & Care found no major safety or tolerability issues, only transient gastrointestinal symptoms lasting 3 to 5 days, for the novel probiotic product.

Full Story: